Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin announced that results from its Phase 1a trial of LNP8701, a novel SOS1 inhibitor for treating metastatic solid tumors, have been published at the ASCO 2026 Annual Meeting. The trial showed LNP8701 was well tolerated with favorable safety, pharmacokinetics, and anti-tumor activity. Three patients achieved stable disease, with two completing 12 cycles and one completing 14 cycles of treatment. Lupin plans to continue efficacy studies in Phase 1b trials in India, exploring both monotherapy and combination treatment potential for solid tumors.
Positive news for shareholders as it demonstrates progress in Lupin's oncology pipeline. While this is early-stage data and not a product approval, successful Phase 1 results could enhance the company's long-term growth prospects in the cancer treatment market.